2023-505279-62-00
Active, Not Recruiting
Phase 1/2
A Phase 1/2a Study of Safety, Pharmacokinetics and Neutralizing Activity of SPK002 as pre-exposure prophylaxis of COVID-19 in healthy volunteers (Phase 1) and immunocompromised individuals (Phase 2a).
Spikimm1 site in 1 country78 target enrollmentJuly 3, 2023
Overview
- Phase
- Phase 1/2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Spikimm
- Enrollment
- 78
- Locations
- 1
- Status
- Active, Not Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Antoine Pau
Scientific
Spikimm
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy SubjectsNCT07300189OrsoBio, Inc288
Active, Not Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer2023-506700-12-00Genentech Inc.45
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer2023-504013-68-00Genentech Inc.46
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors2023-504709-35-00Genentech Inc.44
Active, Not Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43